New Key Statistics Module, Z-Score and F-Score
NYSE:TAK Key Ratios
| Market Cap $ M | 41,011.44 |
| Enterprise Value $ M | 69,101.38 |
| P/E(ttm) | 32.51 |
| PE Ratio without NRI | 32.51 |
| Forward PE Ratio | 23.27 |
| Price/Book | 0.95 |
| Price/Sales | 1.56 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | 17.10 |
| Payout Ratio % | 1.57 |
| Revenue (TTM) $ M | 29,415.00 |
| EPS (TTM) $ | 0.40 |
| Beneish M-Score | -2.69 |
| 10-y EBITDA Growth Rate % | 6.10 |
| 5-y EBITDA Growth Rate % | 10.00 |
| y-y EBITDA Growth Rate % | -2.00 |
| EV-to-EBIT | 30.14 |
| EV-to-EBITDA | 9.05 |
| PEG | 3.25 |
| Shares Outstanding M | 3,137.83 |
| Net Margin (%) | 4.28 |
| Operating Margin % | 8.08 |
| Pre-tax Margin (%) | 3.56 |
| Quick Ratio | 0.55 |
| Current Ratio | 1.06 |
| ROA % (ttm) | 1.25 |
| ROE % (ttm) | 2.68 |
| ROIC % (ttm) | 3.00 |
| Dividend Yield % | 4.82 |
| Altman Z-Score | 1.04 |
TAK Number of Guru Trades
TAK Volume of Guru Trades
Gurus Latest Trades with NYSE:TAK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NYSE:TAK is held by these investors
Total 1
Takeda Pharmaceutical Co Ltd Insider Transactions
No Available Data
News about NYSE:TAK
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers